In vitro, HER2-CAR-T cells exhibit robust targeted killing activity against a variety of solid tumors, including ovarian cancer (101), breast cancer (102), gastric cancer (33), pancreatic cancer (103), melanoma (104), glioblastoma (105), and head and neck cancer (106). This evidence concerns the gene ERBB2 and ovarian carcinoma.